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We	   present	   a	   case	   of	   an	   old	   woman	   with	   previously	   documented	   heparin-­‐induced	  
thrombocytopenia	   (HIT),	   treated	   with	   fondaparinux,	   who	   presented	   with	   thrombocytopenia	   and	  
venous	  thrombosis	  after	  exposure	  to	  a	  preventive	  dose	  of	  fondaparinux	  during	  orthopaedic	  surgery.	  
Any	  accidental	  exposure	  to	  heparin	  was	  avoided.	  Other	  causes	  of	  thrombocytopenia	  were	  excluded	  
and	  antigenic	  tests	  combined	  with	  clinical	  probability	  made	  a	  diagnosis	  of	  HIT	  likely.	  
Can	   this	   be	   considered	   a	   possible	   case	   of	   fondaparinux-­‐related	  HIT,	   despite	   the	   intense	   and	   early	  
decrease	  in	  platelets,	  as	  usually	  happens	  in	  rapid-­‐onset	  HIT,	  and	  the	  fact	  that	  previous	  exposure	  to	  
fondaparinux	  had	  occurred	  5	  months	  previously?	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Introduction	  
Heparin-­‐induced	   thrombocytopenia	   (HIT)	   is	   an	   immune-­‐mediated	   disorder	   caused	   by	   antibodies	  
against	  platelet	  factor	  PF4/heparin	  complexes	  characterized	  by	  an	  increased	  risk	  of	  thromboembolic	  
complications1.	  
The	   risk	   is	   greater	  with	   the	   use	   of	   unfractionated	  heparin	   (UFH),	   ten	   times	   lower	  with	   the	   use	   of	  
low-­‐molecular-­‐weight	   heparin	   (LMWH)	   and	   negligible	   with	   the	   use	   of	   fondaparinux,	   a	   direct	   Xa	  
inhibitor2.	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and	  few	  anecdotal	  cases	  are	  described.	  
Case	  
We	   report	   on	   a	   case	   of	   suspected	   heparin-­‐induced	   thrombocytopenia	   with	   thrombosis	   (HITT)	  
associated	   with	   the	   use	   of	   fondaparinux	   in	   an	   82-­‐year-­‐old	   woman	   with	   a	   previous	   HITT	   with	  
documented	  deep	  venous	  thrombosis	  (DVT)	  and	  right	  pulmonary	  embolism	  (PE)	  during	  prophylaxis	  
with	   LMWH	   after	   a	   minor	   hip	   fracture.	   The	   diagnosis	   was	   performed	   by	   association	   of	   high	  
probability	   of	   HIT	   according	   to	   the	   “4Ts	   Score”1	   and	   high-­‐titre	   anti-­‐PF4/heparin	   antibodies	  
determined	  with	  ELISA	  standard	  (GTI-­‐PF4),	  after	  exclusion	  of	  other	  causes	  of	  thrombocytopenia.	  She	  
was	  treated	  with	  fondaparinux	  and,	  when	  the	  platelet	  count	  was	  normalized,	  with	  warfarin.	  
Five	   months	   later,	   still	   in	   anticoagulation	   with	   warfarin,	   she	   suffered	   a	   left	   hip	   fracture	   which	  
required	  prosthetic	  hip	  replacement.	  Surgery	  was	  delayed	  for	  5	  days	  because	  of	  the	  onset	  of	  fever	  of	  
unclear	  origin	  treated	  with	  a	  high-­‐spectrum	  antibiotic.	  
The	  day	  of	  surgery,	  fondaparinux	  2.5	  mg/day	  was	  started.	  The	  platelet	  count	  was	  390,000/mmc	  and	  
the	   International	   Normalized	   Ratio	   (INR)	   2.69	   before	   substitution	   with	   fondaparinux,	   such	   that	  
vitamin	  K	  (2	  mg	  orally)	  was	  given.	  Because	  of	  the	  previous	  history	  of	  HITT,	  any	  incidental	  exposure,	  
either	  intra-­‐	  or	  peri-­‐operatively,	  to	  UFH	  or	  LMWH	  was	  carefully	  avoided.	  




A	  bilateral	  PE	  and	  an	  extension	  of	  the	  previous	  DVT	  were	  diagnosed.	   	  
Fibrinogen,	   Prothrombin	   Time	   (PT),	   Partial	   Thromboplastin	   time	   (PTT)	   and	   Antithrombin	   III	   (ATIII)	  
had	  normal	  values.	  Anti-­‐heparin/PF4	  antibodies	  (GTI-­‐PF4)	  were	  detected	  in	  high	  titres	  (OD>1.2).	  The	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according	  the	  “HEP	  score”1,3.	  The	  timing	  and	  the	  degree	  of	  thrombocytopenia	  and	  the	  onset	  of	  new	  
thrombotic	  manifestations	   in	  the	  absence	  of	  an	  alternative	  diagnosis	  made	  us	  suspect	  a	  relapse	  of	  
HIT,	  although	  the	  previous	  exposure	  to	  fondaparinux	  was	  almost	  150	  days	  before.	   	  
Consequently,	  lepirudin	  treatment	  was	  instituted.	  
No	  cases	  of	  HIT	  associated	  with	  the	  use	  of	  fondaparinux	  were	  found	  in	  trials	  conducted	  in	  different	  
clinical	  settings,	  which	  had	  been	  used	  successfully	  to	  treat	  HIT1.	  
Theoretically,	   the	   limited	   interactions	   of	   fondaparinux	   with	   PF4	   and	   the	   lack	   of	   in	   vitro	  
cross-­‐reactivity	  with	  HIT	   antibodies	   have	   led	   to	   the	   general	   agreement	   that	   fondaparinux	   is	   likely	  
non-­‐immunogenic,	   suggesting	   its	   use	   in	   HIT.	   However,	   antiPF4-­‐heparin	   antibodies	   have	   been	  
detected	  in	  patients	  receiving	  thrombophylaxis	  with	  fondaparinux	  with	  an	  incidence	  similar	  to	  that	  
observed	  in	  patients	  receiving	  LMWH	  enoxaparin,	  although	  without	  any	  associated	  HIT2.	  
Warkentin	   hypothesized	   a	   low	   –	   though	   not	   zero	   –	   risk	   either	   of	   inducing	   HIT	   ex	   novo	   or	   of	   HIT	  
relapse	   when	   antibodies	   are	   already	   present2.	   In	   the	   literature,	   a	   causal	   association	   between	  
fondaparinux	  therapy	  and	  the	  occurrence	  of	  HIT	  is	  described	  only	  in	  anecdotal	  case	  reports1.	  
In	  our	   case,	   the	  delayed	   surgery,	   the	  administration	  of	   vitamin	  K	  and	   the	   inflammatory	   state	  may	  
have	  aided	  the	  pro-­‐thrombotic	  state,	  but	  no	  other	  causes	  of	   thrombocytopenia	  were	   identified.	   In	  
particular,	   there	   were	   no	   signs	   of	   disseminated	   intravascular	   coagulation	   (DIC)	   or	   drug-­‐induced	  
thrombocytopenia.	  Can	  this	  be	  considered	  a	  rare	  case	  of	  fondaparinux-­‐induced	  thrombocytopenia?	  
Due	  to	  the	  rapidity	  and	  intensity	  of	  the	  fall	  in	  platelet	  count	  together	  with	  the	  severity	  of	  the	  clinical	  
conditions,	   the	   present	   case	   seems	   to	   be	   one	   of	   “rapid-­‐onset	   HIT”,	   even	   though	   the	   exposure	   to	  
fondaparinux	  was	  over	  150	  days	  prior	  and	  the	  persistence	  of	  antibodies	  should	  be	  considered	  highly	  
unlikely.	   Alternatively,	   we	   could	   be	   dealing	   with	   a	   “spontaneous	   HIT”	   in	   which	   both	   clinical	   and	  
serological	   aspects	   are	   identical	   to	  HIT,	   but	  with	  no	  heparin	   exposure.	   In	   this	   case,	   PF4	   tetramers	  
may	   have	   had	   a	   role	   in	   platelet	   activation.	   They	  may	   have	   been	   rendered	   immunogenic,	   through	  
exposure	   to	   either	   a	   polyanionic	   bacterial	   surface	   or	   chondroitin	   sulphates	   released	   during	  
orthopaedic	   surgery,	   or	   through	   some	   other,	   unknown,	   mechanism4.	   A	   delayed-­‐onset	   HIT,	   as	  
described	  by	  Alsaleh	  et	  al.5,	  triggered	  by	  the	  previous	  administration	  of	  LMWH	  seems	  less	   likely	  as	  
five	   months	   had	   elapsed	   from	   the	   last	   administration	   of	   this	   drug,	   and	   the	   antibody	   immune	  
response	  is	  usually	  short	  lived.	  
Unfortunately,	  we	   could	  not	  perform	  a	   functional	   assay,	  which	  would	  have	  helped	   to	   identify	   the	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• Heparin-­‐induced	  thromboctitopenia	  (HIT)	  is	  an	  extremely	  rare	  condition.	  
• A	  causal	  association	  between	  fondaparinux	  use	  and	  HIT	  has	  not	  been	  established	  and	  only	  
few	  anecdotal	  cases	  are	  described	  
• In	   this	   report	  we	  describe	  a	  case	  of	  HIT	  after	  exposure	  to	  Fondaparinux;	   it	   is	  not	  clear	   if	   it	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